Key Takeaways

  • 25-40% of weight lost on GLP-1 medications is lean tissue (including muscle), particularly in older patients and those who don't strength-train
  • Three biologic drugs in late-stage development target this problem: bamagrumab (Lilly, Phase 3 with tirzepatide), taldefgrobep (Biohaven, Phase 3 in SMA), trevogrumab (Regeneron, earlier stage)
  • Bamagrumab is closest to approval, with Phase 3 results expected to support FDA submission in 2026-2027
  • Patient groups most likely to benefit: adults over 60, those with baseline sarcopenia, those losing >15% body weight, those who can't do resistance training
  • Until these drugs arrive, the standard tools work: resistance training, 1.6-2.2 g/kg/day protein, slower weight loss in older patients

Every GLP-1 weight loss success story has the same hidden cost. When you lose 50 pounds on semaglutide or tirzepatide, somewhere between 25 and 40 percent of that loss is lean tissue, including skeletal muscle. The fat goes, but the muscle goes with it.

For young, active patients who are also doing resistance training and eating sufficient protein, the muscle loss is manageable. For everyone else, it's an open clinical problem. Older patients are particularly vulnerable. Sarcopenia — age-related muscle loss — is already a major contributor to disability and mortality after 65. Adding GLP-1-driven muscle loss on top of natural sarcopenia in an older patient is not a great clinical setup.

The pharmaceutical industry has noticed. Three biologic drugs in late-stage development target this exact problem.

Why muscle loss happens during weight loss

When you eat fewer calories than you burn, your body draws on stored energy to make up the difference. The preference is to burn fat. The reality is that body composition during weight loss is usually a mix of fat and lean tissue, not pure fat.

Several factors push the ratio toward more muscle loss:

  • Rapid weight loss tends to produce more lean-tissue loss than gradual weight loss
  • Insufficient dietary protein leaves the body with no choice but to break down muscle protein for amino acids
  • Lack of resistance training removes the signal that tells the body to preserve muscle
  • Older age tilts the body's natural balance toward catabolism (breakdown) over anabolism (building)

GLP-1 medications produce relatively rapid weight loss compared to lifestyle interventions. They also tend to suppress appetite enough that patients eat less protein than they should, often unintentionally. The combination can drive higher-than-ideal muscle loss in a non-trivial subset of patients.

What myostatin does

Myostatin is a regulatory protein that puts a ceiling on muscle growth. Discovered in the 1990s, it acts on muscle stem cells to limit how much they proliferate and how much new muscle they build. Animals genetically engineered to lack myostatin develop dramatically larger muscles. Cattle bred for natural myostatin mutations are the source of the famously hyper-muscular Belgian Blue and Piedmontese breeds. A handful of human cases of natural myostatin deficiency have been documented, all involving unusual muscularity from infancy.

The drug development logic is straightforward. If myostatin limits muscle, blocking myostatin should preserve or grow muscle. The catch is that the natural function of myostatin matters — the body has the brake for a reason — so the goal is partial inhibition, not complete elimination.

Bamagrumab (Eli Lilly)

Bamagrumab targets ActRIIA and ActRIIB, the receptors that myostatin binds to in order to signal muscle cells. Blocking the receptor blocks the myostatin signal regardless of how much myostatin is in circulation.

In Phase 2 trials, bamagrumab produced increases in lean muscle mass and decreases in fat mass in older obese patients, even without an explicit caloric deficit. The pattern was striking enough that Lilly accelerated development specifically as a companion drug for GLP-1 medications.

The Phase 3 program is testing bamagrumab paired with tirzepatide in patients undergoing weight loss. The hypothesis is that the combination will produce the same total weight loss as tirzepatide alone, with a much higher percentage of the loss coming from fat rather than muscle. Early data supports the hypothesis.

If the Phase 3 trial confirms the benefit, expect FDA submission in 2026 to 2027 and approval some months later. The clinical question then becomes how to identify which GLP-1 patients should be on the combination. Plausible criteria include age over 60, baseline sarcopenia, planned weight loss exceeding 15 percent of body weight, or inability to perform resistance training.

Taldefgrobep (Biohaven)

Taldefgrobep targets myostatin directly rather than the receptor. It is furthest along for spinal muscular atrophy (SMA), a genetic disease that causes progressive muscle weakness, where it has shown promising results in clinical trials.

The same mechanism that helps SMA patients preserve muscle would, in principle, help any patient at risk of muscle loss. Biohaven and academic researchers have explored taldefgrobep for sarcopenia, post-surgical recovery, and weight-loss-associated muscle loss. The dataset is smaller than bamagrumab's, but the mechanism is well-validated.

If taldefgrobep reaches market for SMA first, it would be available for off-label use in other muscle-preservation contexts. Off-label prescribing for biologics is heavily constrained by insurance coverage rules, so practical access for GLP-1 patients would depend on either an explicit weight-loss indication or willingness to pay cash.

Trevogrumab (Regeneron)

Trevogrumab is at an earlier stage of development. It targets myostatin at a different point in the activation cascade, blocking the conversion of latent myostatin to its active form. The pharmacological profile is different from the other two — possibly fewer off-target effects, possibly less potent muscle preservation. The trade-offs will become clearer as trials progress.

Regeneron has not specifically positioned trevogrumab for the GLP-1 companion market, but the basic mechanism applies. If the drug reaches approval for any muscle-preservation indication, the GLP-1 use case would follow.

What this means for the GLP-1 patient

For the next 18 to 24 months, the only available muscle-preservation tools for GLP-1 patients remain the standard ones:

  • Resistance training, prioritized in the routine
  • Adequate protein intake, typically 1.6 to 2.2 grams per kilogram of body weight per day
  • Slower weight loss when possible, especially for older patients
  • Testosterone optimization in men with low baseline levels

These tools work. The Phase 3 myostatin inhibitor trials use them as the comparator arm precisely because they're the current standard of care.

What changes when bamagrumab or a similar drug becomes available is the ceiling on what's achievable for the patients who can't or won't do all of the above. An older patient with no history of strength training who is going to lose 80 pounds on tirzepatide is currently almost guaranteed to lose substantial muscle. With a myostatin inhibitor in the protocol, that math changes.

The cost of these biologics will be high. Bamagrumab's Phase 3 economics will likely require monthly pricing in the range of other obesity-class biologics, on top of the GLP-1 cost. For patients paying cash, the combined monthly bill could exceed $1,500 to $2,000. Insurance coverage will depend entirely on how the FDA-approved label reads and how payers respond.

The bigger picture

Myostatin inhibitors are part of a broader pattern in obesity medicine: the field is rapidly building a stack of drugs designed to address the specific failure modes of weight loss, rather than relying on a single all-purpose treatment. GLP-1s drive the weight loss. Myostatin inhibitors preserve the muscle. Bone-density-protecting agents are likely next. Eventually, the standard prescription for medical weight management may resemble HIV cocktail therapy — multiple drugs, each addressing a specific component of the problem.

That is a meaningful evolution from the previous generation of weight-loss drugs, which were single agents with significant compromises. The cost trajectory is concerning. The clinical effectiveness trajectory is genuinely impressive.

Patients starting a GLP-1 today should be aware of the muscle-loss risk and address it with the tools currently available. Patients starting in 2027 or later may have a different and better set of options.